Изработка на уеб сайт от Web IT Solutions

FOx Biosystems

FOx Biosystems

Visit website
Fox Biosystems

Portfolio company


Sector: Medical Devices & Diagnostics

FOx BIOSYSTEMS’s mission is to revolutionize the Life Science and Pharmacological research markets with innovative real-time, label-free analysis products.

The basis of the company’s success is a novel fibre-optic-based surface plasmon resonance (FO-SPR) biosensor which enables users to generate high-quality, cost-effective biomolecular data accurately, fast, and over a wide range of applications. The White Fox technology uses an innovative fibre-optic probe setup which combines a fluidics-free dip-in protocol with the precision and speed of surface plasmon resonance (SPR). This means it can be used directly in complex samples, like lysates, whole blood or large particles. The probes can be switched easily to allow the detection of different target molecules, including antibodies, nanobodies, microvesicles, phage and small molecules, with a single device.


Investing in start-ups and early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution. It should be done only as part of a diversified portfolio. Any investments are targeted exclusively at investors who understand the risks of investing in early-stage businesses and can make their own investment decisions. Any pitches for investment are not offers to the public. Investments made in investee companies via funds managed by Sapphire Capital Partners LLP are not covered by the Financial Services Compensation Scheme (FSCS). For more details, please contact us or refer to their website: https://www.fscs.org.uk


Don’t invest unless you’re prepared to lose all the money you invest. This is a high risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.